The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wondered about this SP drop too, LedZepper. Obviously a leak as you say could have prompted it, but it could also have been a few sales prompting other people to worry and bank profits after the recent rise. I considered both selling and buying more and in the end decided just to sit tight as I view this as a long-term investment in a well-run company.
It’s been disconcerting to see such a significant drop in share price over the past few days. Certainly leads to a suspicion of a poor update on Pollinex Quattro trial results as mentioned by Padd1. There are some AIM shares that are notoriously leaky, but I hadn’t considered this to be one of them.... until now, since the volumes are significant too.
However, on a positive note, it seems that we have significant price support at ~33p which still puts us way ahead of historic prices. I’ve decided to wait this out.
9% fairly big move down for this stock !!!
It's continuing and more than a little concerning
I appreciate it's a small float on these shares which means SP can be a little volatile at times. But I'm a bit suspicious of the last couple of days trading - it has been nearly all sells from what I can see. I hope this isn't selling on poor trial results that might have leaked out!
According to recent results, results from the Grass Mata MPL study supposed to be released Autumn this year. Must be soon.
All gone quiet. When do we think there might be any news / update on trials?
I don't thin results are due until March and just wondered if we'd hear anything soon.
Morning. Short interview with CEO/ CFO following this mornings results:
www.fmp-tv.co.uk/2021/09/23/allergy-therapeutics-record-operating-profits-40m-cash/
thanks!
sorry about that....third time luck
AGY
https://www.proactiveinvestors.co.uk/companies/news/961151/allergy-therapeutics-reveal-record-pre-rd-operating-profit-with-continued-sales-growth-961151.html
here's the right one
https://www.proactiveinvestors.co.uk/companies/news/961161/arecor-therapeutics-rapid-insulin-promise-in-early-stage-clinical-trial-and-cash-for-pipeline-961161.html
cheers,to many mushrooms.lol.
this is Arecor, ticker AREC.L not AGY
looks exciting for holders there
Great results what’s not to like, very undervalued this company, only a matter of time before one of the major investors increases holdings
- Record pre-R&D operating profit ahead of market expectations reflecting continued sales growth
- Successful ex-vivo VLP Peanut biomarker study showing 24-fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022
- Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to support Grass MATA MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial
Financial highlights
· 8% revenue growth in actual terms and 6% at constant rate* to £84.3m (2020: £78.2m)
· 19% increase in pre-R&D operating profit to £16.9m (2020: £14.2m) as a result of sales growth and lower overhead cost growth
· Strong cash balance of £40.3m at 30 June 2021 (2020: £37.0m)
· Net profit of £2.9m for the year (2020: Net profit of £7.1m including cash settlement of £3.2m)
Operating highlights (including post period)
· Successful ex-vivo VLP Peanut biomarker study ahead of Phase I trial (named PROTECT) anticipated in Q1 2022
· Robust growth across all key products and countries in a challenging year
· Successful launch of ImmunoBON in Germany and Austria
· Grass MATA MPL exploratory field trial to read out in autumn 2021
· Registration of Venomil in Austria
Manuel Llobet, CEO of Allergy Therapeutics, stated: "Allergy Therapeutics has performed well in 2021, driving our European commercial business and progressing our clinical programmes amid challenging conditions. Our commercial and pipeline products demonstrate our commitment to allergy and immunology solutions to help people worldwide.
"Engaging with our stakeholders is key to our success as a business. They trust us to deliver safe and effective products on time, to stand by our values and to operate our business with high standards of quality and integrity. Our three core values - Vision, Commitment and Menschlichkeit (Humanity), shape the way in which we work and are at the heart of every decision we make. I would like to thank our team and all our partners for their contribution to another successful year."
Analyst briefing and webcast today
Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a virtual presentation for analysts to provide an update on the Group, followed by a Q&A session, at 09.30am BST.
The live webcast can be accessed here.
From the June Trading update: The Group plans to announce its audited preliminary results on 23 September 2021.
Only thing I can see is the pod cast coming up on the 29th so perhaps people anticipating positive recommendation. Shares are also not very liquid which helps when demand increases :) Still, like you not complaining.
Anyone know the reason for the hike in sp today? +8% - not that i'm complaining.
I am hoping that with the recent award for ImmunoBON, we hear exciting news on projected sales to America and other countries. Having recognition should bring in more revenues than first forecasted
https://www.proactiveinvestors.co.uk/companies/news/960502/allergy-therapeutics-says-new-allergy-treatment-wins-german--most-innovative-product-2021--award-960502.html
A chance to hear more detail after RNS and ask questions as l am in a positive frame of mind with AT
https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-280921
Great news and the SP is really starting to gain traction now. Looking good
Allergy Therapeutics announces details of secondary endpoints
from successful VLP Peanut 001 trial
- Ex-vivo data for VLP Peanut support a beneficial efficacy profile
- Demonstrates reduced ability to trigger immune cells associated with allergic reactions
- Findings complement primary outcome of hypoallergic potential of VLP Peanut and provide confidence in upcoming VLP Peanut first in-human Phase I PROTECT study
13 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, today announces the secondary endpoint results from an ex-vivo biomarker study VLP001 which evaluated the Group's novel virus-like particle (VLP) based peanut allergy vaccine candidate ("VLP Peanut").
The secondary endpoint results demonstrated a reduced IgE binding capacity to B cells of VLP Peanut suggesting a promising safety profile with reduced potency to induce allergic reactions.
Further, the results provide a strong indication for the products' efficacy potential, promoting a class switch from the allergic Th2 pathway to the more tolerogenic Th1 pathway;
· Lower ability to elicit Th2 and Tfh (T follicular helper) cells
· Strong ability to promote IFN- ? and Th1 cells
· Promotion of selected regulatory B cell subsets
Previously announced primary endpoint data demonstrated a significant 24-fold reduction in basophil activation and histamine release compared to exposure to the major allergen Ara h2, these results provide strong confidence in the beneficial immunologic mode of action of VLP Peanut.
The VLP001 study took place at Imperial College London and evaluated the Group's short-course VLP Peanut vaccine candidate. In combination with the primary outcome data, these secondary endpoint results are encouraging and provide strong support for the human translation of the pre-clinical results and strong confidence in the data to be generated in the planned Phase I PROTECT study. The data also provide important information to establish the starting dose for PROTECT, which is expected to commence in Q1 2022.
The Group's Chief Executive Officer, Manuel Llobet, will host a webinar on Friday 17th September, when he will be joined by Dr. Mohamed Shamji of Imperial College London, who will provide an overview of the results of the VLP001 study. In addition, Dr. Matthew Heath, Principal Scientist at Allergy Therapeutics will be discussing the scientific background of the vaccine candidate and the concept of using VLPs to address peanut allergy. Those wishing to view the webinar are encouraged to visit the Group website
https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=15182551
This is the RNS as published on AGY’s website
Dr Heath credential looks good
https://www.imperial.ac.uk/people/m.shamji99